Cancer has been a growing concern affecting more than eight million people across the globe. Statistics published by the World Health Organization stated that more than 60% of cancer cases occur in Africa, Asia, and South and Central America.
Cancer has been a growing concern affecting more than eight million people across the globe. Statistics published by the World Health Organization stated that more than 60% of cancer cases occur in Africa, Asia, and South and Central America. The organization also projected that the number of cancer cases could reach 22 million by 2032. Lung, liver, stomach, colorectal, and breast are among the leading cause of cancer deaths. The high mortality rate and wide prevalence of cancer have driven scientists to engage in the discovery of better treatment options of the disease. Alkylating agents were among the earliest classes of drugs available for treating cancer. These are the first nonhormonal drugs successfully used in the cancer treatment. Traditionally, alkylating agents are grouped into SN1 and SN2 types. The SN1 agents directly react with biological molecules. The SN2 type agents are those that form an intermediate, which then react with the biological molecules. Alkylating agents act by damaging the DNA strands and prevent cancer cells from replicating. These agents show activity against the cancer cell during each phase of its life cycle, thus making alkylating agents desirable for treating a wide range of cancers. As alkylating agents act by altering the DNA strands, prolonged use of about 5 years to 10 years of these agents can lead to bone marrow damage, and, in rare instances, it might lead to acute leukemia. Temodar (temozolomide) by Merck, Treanda (bendamustine) by Teva Pharma, and Eloxatin (Oxaliplatin) by Sanofi are the major drugs in this class. Temodar and Eloxatin lost their exclusivity in 2013 and 2012, respectively.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35678
The rising prevalence of different cancer types such as lymphoma, carcinoma, leukemia, and bladder cancer is a major growth driver for the global alkylating agents market. Sedentary and unhealthy lifestyles and environmental changes are factors leading to the increasing prevalence of cancer. Alkylating agents are used in chemotherapy for 100 different cancer types known till date. In addition, rising awareness about various forms of cancers and their treatment is one of the key factors for the growth of the global alkylating agents market.
The global alkylating agents market has been segmented based on type, route of administration, distribution channel, and region. In terms of type, the market is segmented into five major classes: nitrogen mustards, alkyl sulfonates, nitrosoureas, triazines, and ethylenimines. The dosage and schedule of each type of alkylating agent depend on the patient’s overall health, weight and cancer type which is to be treated. Nitrogen mustards include drugs such as mechlorethamine, ifosfamide, melphalan, chlorambucil, and cyclophosphamide. Nitrosoureas class of alkylating agents consists drugs such as streptozocin, carmustine, and lomustine. Alkyl sulfonates include drugs such as busulfan, treosulfan, and mannosulfan. Ethylenimines include drugs such as thiotepa and altretamine. Triazenes include drugs such as dacarbazine and temozolomide. In terms of route of administration, the market is segmented into oral route and intravenous route. In terms of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, online retailers, and private clinics.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=35678
Geographically, the global alkylating agents market is segmented into five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the largest market share owing to high research and development, favorable reimbursement policies, and availability of advanced health care infrastructure. The implementation of the Affordable Care Act has significantly posed limitations to hospitals as well as pharmaceutical companies with respect to costing of new drugs. Europe is the second largest market globally due to the presence of high quality scientific companies and research organizations. However, lack of proper reimbursement policies and regulatory framework pertaining to new drug development are key restraints which might hamper the market growth in Europe.
Pre Book Alkylating Agents Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=35678<ype=S
Key players operating in the global alkylating agents market include Merck & Co., Inc., Cipla Inc., and Pfizer Inc.
More Trending Reports by Transparency Market Research:
Testosterone Replacement Therapy Market: According to Transparency Market Research’s latest report on the global testosterone replacement therapy market for the historical period 2017–2018 and forecast period 2019–2027, increasing incidence of testosterone deficiency, growing awareness among people regarding testosterone replacement therapy and significant pipeline of medications, are projected to drive the global testosterone replacement therapy market during the forecast period
Digital Pregnancy Test Kits Market: Pregnancy test is an indicative marker test for determination of pregnancy, which measures the human chorionic gonadotropin (HCG) in urine samples. The HCG hormone is present in the human body only during pregnancy, which makes it possible for the test to provide accurate results. Various types of pregnancy tests are available in the market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/